Randomized, multicenter, phase 3 study of 1st-line irinotecan+5FU/folinic acid vs cisplatin+5FU in patients with advanced gastric cancer - quality of life analysis

Basit Öğe Kaydı
dc.contributor.authorPozzo, C.
dc.contributor.authorZaluski, J.
dc.contributor.authorDank, M.
dc.contributor.authorBarone, C.
dc.contributor.authorValvere, V.
dc.contributor.authorPeschel, C.
dc.contributor.authorWenczl, M.
dc.contributor.authorGoker, E.
dc.contributor.authorBugat, R.
dc.date.accessioned2019-10-27T19:22:49Z
dc.date.available2019-10-27T19:22:49Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.identifier.endpage204en_US
dc.identifier.issn1359-6349
dc.identifier.issue2en_US
dc.identifier.startpage204en_US
dc.identifier.urihttps://hdl.handle.net/11454/39124
dc.identifier.volume3en_US
dc.identifier.wosWOS:000247564800696en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofEjc Supplementsen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleRandomized, multicenter, phase 3 study of 1st-line irinotecan+5FU/folinic acid vs cisplatin+5FU in patients with advanced gastric cancer - quality of life analysisen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu